OCGN
NASD Ocugen Inc$0.9472 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.9472, $0.0333 below the day’s high of $0.9805
- YTD change
- -29.84%
- vs 20-day SMA
- -7.20%
- vs 200-day SMA
- -36.15%
Price ranges
Price & Performance
-0.84 (-47.08%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 95.0% away from all-time highs of $18.7700
- OCGN is down 30% since the beginning of the year
- OCGN is down 45% over the past 12 months
- OCGN is down 7% over the past 1 month
- 32% of all OCGN investors are betting against OCGN
OCGN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -40.8%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0180
- Last 5 days
- -7.14%
- vs 8-day SMA
- -6.02%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
